RELAPSING REMITTING MULTIPLE SCLEROSIS

This study tests whether ocrelizumab works better than fingolimod at preventing relapses in children and teens (ages 10 to under 18) with relapsing-remitting multiple sclerosis. Participants receive either drug for at least 24 weeks, and researchers track relapse rates and brain …

This study tests whether people with relapsing-remitting MS who have been stable for a year might do better by switching to the drug ofatumumab instead of staying on their current treatment. It also checks if a blood marker called neurofilament light (NfL) can predict who benefit…

This study tests a new treatment that uses a patient's own immune cells (dendritic cells) to help control relapsing-remitting multiple sclerosis (MS). About 45 adults with MS will receive this cell therapy along with their usual MS medications. The goal is to see if the combinati…

This study looks at whether a healthy lifestyle—including diet, stress management, and exercise—can be as good as standard medications for reducing symptoms and improving quality of life in people newly diagnosed with multiple sclerosis (MS) or its early stage, clinically isolate…

This study looks at whether eating a better diet and cutting calories can improve physical function, thinking, pain, fatigue, mood, and anxiety in 100 adults with multiple sclerosis. Participants have relapsing-remitting or secondary progressive MS and are overweight or obese. Re…